Apparatus and Method For Delivery of Antimicrobial During a Transdermal Sampling and Delivery Process
20220104732 · 2022-04-07
Assignee
Inventors
Cpc classification
A61B5/157
HUMAN NECESSITIES
A61B5/15134
HUMAN NECESSITIES
A61B5/150969
HUMAN NECESSITIES
A61B5/14514
HUMAN NECESSITIES
International classification
A61B5/145
HUMAN NECESSITIES
Abstract
A device for introducing at least one antimicrobial in an exposed region of a user's skin caused while accessing interstitial fluid includes a substrate having thereon at least one electrically controllable microheating element including at least a microheater portion with multiple electrodes connected to the microheater portion for forming a micropore in the user's skin. A nanofiber mat loaded with at least one antimicrobial material is arranged on the substrate such that it contacts the user's skin and encircles an opening of the micropore formed by the microheating element. In a preferred embodiment, the at least one antimicrobial material is LL-37.
Claims
1. A device for introducing at least one antimicrobial in an exposed region of a user's skin caused while accessing interstitial fluid of a user comprising: a substrate having thereon a mechanism for accessing the interstitial fluid of the user having at least one electrically controllable microheating element including at least a microheater portion with multiple electrodes connected to the microheater portion for causing a micropore in the user's skin by thermal ablation of at least a portion of the skin's stratum corneum; and a nanofiber mat loaded with at least one antimicrobial material, wherein the nanofiber mat is disposed on a skin-facing side of the substrate and is arranged on the skin-facing side such that it contacts the user's skin and encircles an opening of the micropore.
2. The device of claim 1, wherein the nanofiber mat is generally ring shaped.
3. The device of claim 1, wherein the nanofiber mat is loaded with more than one antimicrobial material.
4. The device of claim 1, wherein one of the at least one antimicrobial material is LL-37.
5. The device of claim 1, wherein the substrate includes thereon multiple individually controllable sites for accessing interstitial fluid of a user, each of the multiple individually controllable sites including: a mechanism for accessing the interstitial fluid of the user; and a nanofiber mat loaded with at least one antimicrobial material.
6. The device of claim 5, wherein each mechanism includes at least one electrically controllable microheating element including at least a microheater portion with multiple electrodes connected to the microheater portion.
7. The device of claim 6, wherein each microheating element causes a micropore in the user's skin.
8. The device of claim 7, wherein each nanofiber mat is disposed on a skin-facing side of the substrate and is arranged on the skin-facing side such that it contacts the user's skin and encircles an opening of an associated micropore.
9. The device of claim 5, wherein each nanofiber mat is loaded with more than one antimicrobial material.
10. The device of claim 5, wherein one of the at least one antimicrobial material is LL-37.
11. A hand-held device for electrochemically monitoring an analyte in interstitial fluid of a user comprising: a first end configured to contact the skin of the user, the first end including a mechanism for ablating the skin of the user to form a micropore to access interstitial fluid and further including a nanofiber mat formed thereon, the nanofiber mat including at least one antimicrobial material; a cartridge connected to the first end and having disposed therein a plurality of disposable sensing elements for contacting interstitial fluid from the micropore to monitor an analyte therein; a second end connected electrically and mechanically to the cartridge and the first end for facilitating operation of the mechanism for ablating the skin, dispensing of a disposable sensing element and monitoring of the analyte.
12. The hand-held device of claim 11, wherein the mechanism for ablating the skin includes at least one electrically controllable microheating element including at least a microheater portion with multiple electrodes connected to the microheater portion located at an open-ended tip of the first end.
13. The device of claim 11, wherein the nanofiber mat is arranged on a tip of the first end such that it contacts the user's skin and encircles an opening of the micropore formed by the microheating element.
14. The device of claim 11, wherein the nanofiber mat is loaded with more than one antimicrobial material.
15. The device of claim 11, wherein one of the at least one antimicrobial material is LL-37.
16. A patch including multiple individually controllable sites for accessing interstitial fluid of a user and monitoring at least one analyte therein, comprising: a substrate having formed thereon the multiple individually controllable sites each including: a mechanism for producing a micropore in the user's skin and accessing the interstitial fluid of the user the mechanism having at least one electrically controllable microheating element including at least a microheater portion with multiple electrodes connected to the microheater portion for producing the micropore in the user's skin by thermal ablation of at least a portion of the skin's stratum corneum; and a nanofiber mat loaded with at least one antimicrobial material, wherein the nanofiber mat is disposed on a skin-facing side of the substrate and is arranged on the skin-facing side such that it contacts the user's skin and encircles an opening of the micropore; and an adhesive disposed on the skin-facing side of the substrate for adhering the patch to the skin of the user.
17. The device of claim 16, wherein the nanofiber mat is arranged on the substrate such that it contacts the user's skin and encircles an opening of the micropore formed by the microheating element; and further wherein the at least one antimicrobial material is LL-37.
18. The device of claim 16, wherein the nanofiber mat is loaded with more than one antimicrobial material.
Description
BRIEF SUMMARY OF THE FIGURES
[0011] The Summary of the Embodiments, as well as the following Detailed Description, is best understood when read in conjunction with the following exemplary drawings:
[0012]
[0013]
[0014]
[0015]
[0016]
[0017]
DETAILED DESCRIPTION
[0018]
[0019] The applied voltage specifications, i.e., volts/time, may vary in accordance with patient age and size. For example, devices used on adult human patients may be configured to apply 3V (with respect to ground) for, e.g., 30 msec, resulting in a rapid ablation of a portion of the patient's stratum corneum creating an approximately 50 μm diameter micropore therein. Whereas, the same or a different device, may be configured for use with premature human patients where the stratum corneum has minimal thickness. In this case, one skilled in the art recognizes that the applied voltage, time and resulting pore diameter would be reduced.
[0020] Further, while the specific representative embodiments described and illustrated herein include the nanofiber mat 18 as being part of the microheating element 10, one skilled in the relevant art understands that variations which provide for the nanofiber mat 18 being in close proximity to the resulting micropore 16, but not necessarily on the microheating element 10, fall well within the scope of the present embodiments. For example, referring to
[0021] Additional details regarding the formulation, layout, dimensions and operation of the microheating element 10 are described in the co-owned patents and patent applications (collectively, “Patent Documents”) listed in the Background section above. Multiple microheating elements 10 may be used in an array as discussed in the Patent Documents, wherein multiple individual microheating elements 10 each having a nanofiber mat 18 on or associated therein are included in an array. The array may be included on a substrate, e.g., patch, wherein each of the individual microheating elements 10 is individually controllable/usable, thus resulting in multiple micropores over the course of time and use of the array.
[0022]
[0023]
[0024] Alternatively, the device may be a single-use device. Whether the microheating element is part of a single-use device or a multi-use device, the effectiveness of the nanofiber mat 18 or more specifically, the antimicrobial, may be enhanced by keeping the device in place for a predetermined amount of time, e.g., at least 2 hours, or an approximate amount of time calculated for the micropore 16 in the stratum corneum to begin closing up.
[0025] A description of exemplary processes for formation of the nanofiber mat for use in the embodiment described herein may be found in one or more of the documents listed in the section Documents Incorporated by Reference. The immobilization of antimicrobial peptides and peptide motifs on nanofiber membranes has been achieved and the effectiveness of the antimicrobial nanofiber membranes as both an antibiotic and a wound healing facilitation material has been determined. In a specific exemplary embodiment, the nanofiber mat 18 may be formed using electrospinning techniques to generate nanofibers having varying diameters, e.g., 100-500 nm, from a solution of poly(ethylene-oxide) (PEO) and the antimicrobial peptide, LL-37 as discussed in detail in J. W. Gatti et al., Using electrospun poly(ethylene-oxide) nanofibers for improved retention and efficacy of bacteriolytic antibiotics, Biomed Microdevices, October 2013, Volume 15, Issue 5, pp 887-893.
[0026] The antimicrobial LL-37 is selected as the exemplar microbial herein for its broad bacteria killing ability. More specifically, LL-37 has been shown to kill the following bacteria as discussed in Vandamme et al., “A comprehensive summary of LL-37, the factotum human cathelicidin peptide,” Cellular Immunology 280, pgs. 22-35 (2012): Bacillus anthracis; Enterococcus faecalis; Group A streptococcus; Group B Streptococcus; Lactobacillus casei; Listeria monocytogenes; Micrococcus luteus; Nocardia sp.; Propionibacterium acnes; Staphylococcus aureus; Streptococcus mutans; Streptococcus pneumonia; Borrelia spp.; Mycobacterium bovis; Mycobacterium smegmatis; Mycobacterium tuberculosis; Achromobacter xylosoxidans; Acinetobacter baumannii; Aggregatibacter actinomycetemcomitans; Brucella suis; Burkholderia pseudomallei; Burkholderia cepacia; Burkholderia thailandensis; Capnocytophaga spp.; Escherichia coli; Francisella novicida; Fusobacterium nucleatum; Haemophilus influenza; Helicobacter pylori; Klebsiella pneumonia; Leptospira interrogans; Mannheimia haemolytica; Pasteurella multocida; Porphyromonas circumdentaria; Porphyromonas gingivalis; Prevotella intermedia; Prevotella loescheii; Prevotella melaninogenica; Pseudomonas aeruginosa; Salmonella sp.; Shigella sp.; Stenotrophomonas maltophilia; Tannerella forsythia; Treponema denticola; Treponema pallidum and Yersinia pestis.
[0027] One skilled in the art readily recognizes that other antimicrobials may be used, either alone, or in combination with LL-37 to cover a wider range of bacteria.
[0028] The incorporation of an antimicrobial is also contemplated with respect to, e.g., a hand-held device for electrochemically monitoring an analyte in interstitial fluid of a user, such as that disclosed in co-owned U.S. patent application Ser. No. 13/835,696. Components of an exemplary device 34 are illustrated in
[0029] Although not shown, connective elements located e.g. in the inner wall of device 34 can serve to place elements 37, 39, and/or 50 (as described below) in contact with the controllable voltage source 38.
[0030] With further reference to
[0031] While the particular examples above are directed to certain exemplary transdermal devices, one skilled in the art appreciates that the antimicrobial nanofiber mat or coating may be incorporated into other medical equipment that invades the body, including, but not limited to syringes, catheters, etc.
[0032] As referenced briefly in the Background, the risk of infection at surgical and other wound sites dressed with sutures and/or other closure materials is an on-going concern. The antimicrobial nanofiber materials referenced above may form or be incorporated into various dressings including, but not limited to biodegradable fibrous mesh, biodegradable suture (e.g., a polymer) or non-biodegradable suture (e.g., silk nanofibers) containing LL-37 or other antimicrobial. As with the nanofiber mats described herein, these dressings form a barrier to foreign bodies.